The twice-yearly shot was 100% effective in preventing HIV infections in a study of women, and recently results published show it worked nearly as well in men.
Gilead's new drug, lenacapavir, shows unprecedented success in HIV prevention, offering hope especially for marginalized ...
The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...
I'm sometimes asked how I started in AIDS organizing. Although it’s hard to pin when it happened, I will always remember ...
The HIV vaccine space has seen dwindling research activity as drug manufacturers turn to PrEP therapies for preventive ...
Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...
The twice-yearly HIV prevention shot from Gilead Sciences has proven 100% effective in women and nearly as effective in men, ...
In February, it announced a collaboration with California’s Gilead Sciences to develop the cancer drug Trodelvy in a deal worth up to $210mn. Trodelvy is already approved to treat some cancers ...
South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...
GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback